View source for Atripla

From Proteopedia

Jump to navigation Jump to search

You do not have permission to edit this page, for the following reason:

The action you have requested is limited to users in the group: Users.

You can view and copy the source of this page.

A fixed-dose triple combination of [[emtricitabine]], [[tenofovir]] and [[efavirenz]] (Sustiva, marketed by Bristol-Myers Squibb) was approved by the U.S. Food and Drug Administration (FDA) on July 12, 2006, under the brand name Atripla.

Return to Atripla.

Retrieved from "https://proteopedia.org/Atripla"

Navigation menu